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To determine how much of the clinical variability in facioscapulohumeral muscular dystrophy
type 1 (FSHD1) can be explained by the D4Z4 repeat array size, D4Z4 methylation and familial
factors, we included 152 carriers of an FSHD1 allele (23 single cases, 129 familial cases from
37 families) and performed state-of-the-art genetic testing, extensive clinical evaluation and
quantitative muscle MRI. Familial factors accounted for 50% of the variance in disease severity
(FSHD clinical score). The explained variance by the D4Z4 repeat array size for disease severity
was limited (approximately 10%), and varied per body region (facial muscles, upper and lower
extremities approximately 30%, 15% and 3%, respectively). Unaffected gene carriers had longer
repeat array sizes compared to symptomatic individuals (7.3 vs 6.0 units, P = 0.000) and slightly
higher Delta1 methylation levels (D4Z4 methylation corrected for repeat size, 0.96 vs −2.46,
P = 0.048).
The D4Z4 repeat array size and D4Z4 methylation contribute to variability in disease severity
and penetrance, but other disease modifying factors must be involved as well. The larger effect
of the D4Z4 repeat array on facial muscle involvement suggests that these muscles are more
sensitive to the influence of the FSHD1 locus itself, whereas leg muscle involvement seems
highly dependent on modifying factors.
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1 | INTRODUCTION
Facioscapulohumeral muscular dystrophy (FSHD) is one of the most
common inherited muscle disorders.1 It is characterized by progressive
and typically asymmetrical weakness and wasting of facial, shoulder
girdle and upper arm muscles, and often also trunk and leg muscles.2
The degree of muscle involvement and the rate of disease progression
are highly variable both between and within families.3,4
FSHD is caused by the expression of the DUX4 transcription factor
that is normally suppressed in somatic cells.5,6 A copy of the DUX4 gene
is located within each unit of the D4Z4 repeat array on chromosome
4q35 and a complete DUX4 gene in the most distal D4Z4 unit. In the
normal population this repeat array varies between 8 and 100 units,
whereas in facioscapulohumeral muscular dystrophy type 1 (FSHD1),
the most common form of FSHD, it is contracted to 1 to 10 D4Z4
units.7,8 This contraction leads to a more open D4Z4 chromatin struc-
ture, resulting in a higher chance of DUX4 expression in skeletal muscle.
In FSHD2, the rarer form of FSHD, the more open D4Z4 chromatin
structure is caused by a pathogenic variant in the SMCHD1 or DNMT3B
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gene instead of a repeat contraction.9,10 Both gene products are neces-
sary to establish or maintain a repressive D4Z4 chromatin structure in
somatic tissue. Both in FSHD1 and FSHD2 the mutations only lead to
disease if they are present on specific haplotypes that provide the nec-
essary polyadenylation signal (DUXPAS) to stabilize the DUX4 tran-
script.7,11 A small number of FSHD patients cannot be genetically
explained by these two mechanisms.
For FSHD1 a rough and inverse correlation between the number
of D4Z4 repeat units and disease severity has been repeatedly
described.3,12–15 The majority of patients with 1 to 3 repeat units has
a severe phenotype, while patients with 7 to 10 repeat units tend to
be more mildly affected.16,17 However, variability in disease severity is
large for all repeat array sizes. Within families with repeat array sizes
of 7 to 10 units, asymptomatic or non-penetrant gene carriers are
found frequently (up to 30% of family members).15,18 These longer-
sized repeat arrays are also found in 1% to 2% of the healthy Cauca-
sian population, indicating that they are disease permissive, but not
always pathogenic.19,20
Since the discovery of the disease mechanism for FSHD2, it is
becoming increasingly clear that not only the D4Z4 repeat size, but also
the epigenetic state of the D4Z4 locus contributes to the disease severity
and penetrance. Observations that pathogenic variants in SMCHD1 aggra-
vate disease severity in FSHD1 families suggested that D4Z4 chromatin
modifiers influence DUX4 expression in skeletal muscle.21 This hypothesis
was supported by the lower CpG methylation level that was found in
symptomatic individuals with 7 to 10 repeat units compared to asymp-
tomatic and non-penetrant gene carriers with the same repeat size.22
Still, with the current knowledge on the disease mechanism we
cannot adequately explain the large clinical variability, even within
families. Most likely, disease severity and penetrance are determined
through a complex interplay of genetic, epigenetic and environmental
and/or lifestyle factors. Two of the contributing factors are the D4Z4
repeat array size and D4Z4 chromatin structure (reflected by the
methylation level), although it is unclear how much of the clinical vari-
ability can be explained by these factors. Additionally, because of the
characteristic pattern of muscle involvement, the influence of the
genetic defect and disease-modifying factors may differ between
body regions or muscle groups.
In this study, we combine state-of-the-art genetic testing for
FSHD with extensive clinical data in a large cohort of FSHD1 patients
to assess how much of the clinical variability can be explained with
our current knowledge on the (epi)genetic mechanism. We use family
data to estimate the influence of familial factors on disease severity
and include a detailed description of clinical features to further refine
phenotype-genotype correlations.
2 | MATERIALS AND METHODS
2.1 | Patients
We recruited patients through the Neurology department of the Rad-
boud University Medical Center, the national referral center for FSHD
patients in the Netherlands between 2014 and 2015. We performed
genetic testing on individuals aged 18 years or older and (a) with an
FSHD phenotype, or (b) without an FSHD phenotype, but with at
least one affected first degree family member. All individuals who
tested positive for FSHD1 (D4Z4 repeat array size 1-10 units on a
DUX4PAS containing haplotype) were included.11,19 Exclusion criteria
were the presence of pathogenic variants in SMCHD1 or DNMT3B
and somatic mosaicism for the D4Z4 repeat array contraction. Asymp-
tomatic mutation carriers were defined as individuals aged 25 years
and older who did not report symptoms of FSHD on history taking,
but who showed signs of FSHD on physical examination. Non-
penetrant mutation carriers were aged 25 years and older, reported
no symptoms and had no signs of FSHD on physical examination.
2.2 | Genetic testing
For all samples we isolated blood-derived genomic DNA (gDNA),
which was analyzed for D4Z4 repeat size and haplotype on chromo-
somes 4q and 10q, as previously described.11 Southern blot analysis
of gDNA after digestion with the methylation sensitive restriction
enzyme FseI was used to determine the CpG methylation at the D4Z4
repeats on chromosomes 4 and 10. The Delta1 score as measure for
the degree of D4Z4 hypomethylation was calculated as previously
described.22 D4Z4 CpG methylation is repeat size dependent and the
Delta1 score indicates the differences between the expected D4Z4
CpG methylation based on the number of repeat units, and the
observed methylation.22 Detailed protocols are freely available from
the Fields Center website (www.urmc.rochester.edu/fields-center).
2.3 | Clinical outcome measures
Multiple clinical scores were obtained by a trained clinician (K.M.): the
clinical severity score by Ricci et al is a 10-point for overall disease
severity in which 0 indicates no symptoms and 10 indicates wheelchair
dependency14; the FSHD clinical score assesses disease severity by
assigning severity scores to six body regions and ranges from 0 to 15 in
which higher scores indicate more severe muscle weakness23; the
32-item motor function measure (MFM) tests for functional abilities in
neuromuscular diseases and is expressed as a percentage where a score
of 100% implies no motor deficits.24 Additionally, manual muscle testing
was graded using a 6-point Medical Research Council (MRC) scoring
system25 for the following muscle groups: neck flexors and extensors,
shoulder ab- and adductors and exorotators, elbow flexors and exten-
sors, wrist flexors and extensors, hip flexion, knee flexion and extension,
foot dorsal and plantar flexion. Facial weakness was graded bilaterally
on a self-designed 4-point scale (facial score) for seven different tasks
(closing the eyes gently and firmly, raising the eyebrows, frowning, purs-
ing the lips, showing the teeth and puffing of the cheeks). A sumscore
ranging from 14 to 56 was calculated in which lower scores indicate
more severe facial weakness.
2.4 | Muscle MRI
Ninety patients also participated in a large quantitative muscle MRI
study on FSHD.26 Scanning protocol and data processing are
described in detail elsewhere.26 The MR imaging was performed on a
3-Tesla MR system (TIM Trio; Siemens, Erlangen, Germany). Briefly,
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the legs were scanned using a Dixon 2.0 sequence. Slice thickness
was set at 5 mm. The Dixon sequence fat fraction map was used to
draw a region of interest for each of the leg muscles. Muscle fat frac-
tions were calculated per region of interest. Fat fractions below 15%
are considered normal.27
2.5 | Protocol approval
This study was conducted according to the principles of the Declaration
of Helsinki (version October 2013) and in accordance with the Medical
Research Involving Human Subjects Act (WMO). The study protocol
was approved by the regional medical ethics committee (CMO region
Arnhem-Nijmegen). All participants signed informed consent.
2.6 | Statistical analyses
Statistical analyses were performed using SPSS Statistics version 22 and R
Studio version 3.2. Descriptive statistics (mean, SD, range and frequency)
were calculated for each variable. The relationship between the age-
corrected FSHD clinical score (FSHD clinical score divided by age at exam-
ination) and the D4Z4 repeat array size was studied visually by a scatter
plot and a best fitted trend line based on the least-squared method.
Next, nested linear regression models were fitted to study the frac-
tion of variance in disease severity (FSHD clinical score, dependent vari-
able) explained by each of the variables age, sex, D4Z4 repeat array size
and Delta1 methylation score (independent variables). This was per-
formed by adding the independent variables stepwise to the model to
assess the additional explained variance by each of the added variables.
Because we were mainly interested in the additional value of D4Z4
repeat array size and Delta1 methylation score, the “baseline model”
contained the variables age and sex (Model 1). The variables D4Z4
repeat array size and Delta1 methylation score were each added sepa-
rately (Model 2a and Model 2b) and together to the baseline model
(Model 3). The Glesjer test did not show significant heteroscedasticity
and therefore the nested factors were weighted equally. The procedure
was repeated for all clinical outcomes that were collected.
To study which percentage of the remaining variance can be
explained by familial factors, a random intercept for family was added
to the full fixed effects model (Model 4). The percentage of interest
was estimated as the variance of the random effect divided by the
total variance of the outcome (corrected for the fixed effects). In all
linear models the variable D4Z4 repeat array size is included in the
model as a linear continuous variable, but also transformations of the
variable were considered.
To test for differences in outcomes between the sexes and
between symptomatic and asymptomatic/non-penetrant mutation car-
riers independent samples t tests were used for continuous measures
and χ2 for frequencies. For all statistical tests P-values of <0.05 were
considered statistically significant. For analyses on asymptomatic and
non-penetrant gene carriers, two individuals aged younger than 25 years
without signs or symptoms of FSHD were left out of the analyses.
3 | RESULTS
3.1 | Patient characteristics
We performed genetic testing on 188 individuals. Thirty-six individ-
uals were excluded. Five were excluded because of somatic mosaicism
for the D4Z4 repeat array contraction, 2 carried a pathogenic variant
in SMCHD1 (FSHD2), 22 were unaffected family members of FSHD1
mutation carriers with negative genetic testing for FSHD. Seven other
individuals tested negative for FSHD1 and FSHD2, five of which in
retrospect had a phenotype inconsistent with FSHD. Two individuals
from one family had a typical FSHD phenotype and are still genetically
unexplained. This resulted in a cohort of 152 FSHD1 gene carriers.
There were 23 single cases and 129 familial cases from 37 different
families, with the number of participating family members ranging
from 2 to 12. Baseline characteristics are shown in Table 1. There was
TABLE 1 Patient characteristics
Total cohort n = 152 Females n = 84 Males n = 68
Age in years (mean  SD [range]) 51.1  16.7 [18-84] 50.0  17.1 [18-84] 52.4  16.1 [18-76]
Disease duration in yearsa (mean  SD [range]) 25.6  17.0 [0-64] 26.5  17.5 [0-59] 24.7  16.5 [0-64]
D4Z4 repeat units (mean  SD [range]) 6.2  1.5 [3-9] 6.3  1.6 [3-9] 6.2  1.5 [3-9]
Delta1 methylation score (mean  SD [range]) −1.9  8.4 [−23 to 24] 5 −2.8  8.6 [−23 to 24] −0.8  8.4 [−18 to 22]
Haplotype (n)
A161 147 82 65
A159 5 2 3
Clinical conditionb (n)
Symptomatic 127 69 58
Asymptomatic 14 9 5
Non-penetrant 9 6 3
Clinical severity score (Ricci score) (mean  SD
[range])
5.4  2.9 [0-10] 5.3  2.9 [0-10] 5.4  3.0 [0-10]
FSHD clinical score (mean  SD [range]) 6.4  4.6 [0-15] 6.2  4.7 [0-15] 6.7  4.5 [0-15]
Abbreviation: FSHD, facioscapulohumeral muscular dystrophy.
a Only for symptomatic patients n = 123.
b Two male individuals aged <25 years without signs or symptoms of FSHD were excluded from the analyses. No significant differences between females
and males were found.
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a small overrepresentation of females (55.3%). No significant differ-
ences between females and males were found in age, disease dura-
tion, clinical outcomes and genetic testing results.
3.2 | Explained variance in disease severity
Figure 1 shows a scatter plot of the age-corrected disease severity
(FSHD clinical score) against the D4Z4 repeat array size. Patients with
7 to 9 D4Z4 repeat units were less severely affected than patients
with 3 to 6 D4Z4 repeat units (age-corrected FSHD clinical score 9.7
vs 16.2, P = 0.000). For the Delta1 methylation score no significant
association with age-corrected disease severity was found (Figure 2).
The Delta1 methylation score decreased with an increase in the D4Z4
repeat array size (Table 2). The explained variance (coefficient of
determination R2) for the various nested linear regression models are
given in Table 3.
Within model 1, the fraction of additionally explained variance
was 0.3% for sex (R2 = 0.003). Next, we added a random intercept for
family to the full fixed effects model (model 3), this yielded model
4. The explained variance by the random family factor was approxi-
mately 40%. By leaving out the variable D4Z4 repeat size from the
model, the family component absorbed the degree of explanatory
power of the variable D4Z4 repeat array size and the explained vari-
ance by the random intercept grew to 50% (after correcting for the
fixed effects except D4Z4 repeat size). This indicates that the D4Z4
repeat array size only accounts for 10% of the explained variance in
model 4.
Several transformations of the variable D4Z4 repeat size were
considered, but a linear association with the outcome seemed most
appropriate. Within families the Delta1 score did not explain differ-
ences in disease severity. There were two outliers from one family
with five D4Z4 repeat units with a very severe phenotype (age-
corrected FSHD clinical scores 58 and 65) who had Delta1 scores of
−8 and −6. Excluding them from the analyses did not change the
results.
3.3 | Disease penetrance
This study included 14 asymptomatic and 9 non-penetrant gene car-
riers, excluding two individuals aged younger than 25 years without
signs or symptoms of FSHD. Asymptomatic gene carriers were aged
26 to 79 years (mean 49 years) and non-penetrant gene carriers 33 to
69 years (mean 47 years), and their mean age did not differ from the
symptomatic individuals. There was no difference in the proportion of
asymptomatic and non-penetrant individuals between males and
females. The asymptomatic and non-penetrant gene carriers had a sig-
nificant longer D4Z4 repeat array compared to symptomatic patients
(7.3 vs 6.0 units, 95%-confidence interval [CI] of the difference
−1.929 to −0.601, P = 0.000). All asymptomatic and non-penetrant
carriers had ≥5 D4Z4 repeat units and 18 (78%) had ≥7 repeat units.
The Delta1 score was slightly higher in asymptomatic and non-
penetrant gene carriers than in symptomatic patients with ≥5 D4Z4
repeat units (0.96 vs −2.46, 95%-CI of the difference −7.08 to −0.04,
P = 0.048). There were no differences in D4Z4 repeat array size or
Delta1 methylation score between asymptomatic and non-penetrant
gene carriers.
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FIGURE 1 The age-corrected FSHD clinical score shows a moderate
inverse correlation with the number of D4Z4 repeat units
FIGURE 2 Delta1 methylation score per repeat array size in units for
more mildly and more severely affected individuals (age-corrected
FSHD clinical score <15 and ≥15 respectively) [Colour figure can be
viewed at wileyonlinelibrary.com]
TABLE 2 Disease severity and Delta1 methylation score decrease
when the number of D4Z4 repeat units increases
Number of D4Z4
repeat units
Number of
participants
Age-corrected
FSHD clinical
score
Delta1
methylation score
3 5 25.1  5.0 −1.0  12.4
4 10 17.8  9.9 −1.1  4.4
5 49 16.4  12.8 −1.7  8.4
6 15 11.4  4.7 −2.1  8.2
7 43 11.0  7.1 −2.1  9.6
8 16 9.0  8.0 −1.6  4.3
9 14 6.4  6.1 −4.0  11.1
Abbreviation: FSHD, facioscapulohumeral muscular dystrophy.
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3.4 | Explained variance in disease severity per body
region
We further refined the phenotype-genotype relations by applying the
nested linear models (models 1-3) on various outcome measures for
three body regions: the face, the upper extremities and the lower
extremities (Table 3). We found that approximately 30% of the vari-
ance in the involvement of the facial muscles (facial score) was
accounted for by D4Z4 repeat size (ΔR2 0.313). Severe facial weak-
ness (facial score < 23) was observed only in patients with ≤5 D4Z4
repeat units. The variance explained by the D4Z4 repeat array size
was very limited for the lower extremities (ΔR2 0.006-0.066) and
intermediate for the upper extremities (ΔR2 0.110-0.183). We also
performed these analyses for each of the leg muscles separately (MRI
fat fraction of single muscles) and found an influence of the repeat
array size ranging from only 1% to 4% on the degree of fatty infiltra-
tion in the individual muscles.
The additional variance explained by the Delta1 methylation
score was very limited for all body regions (ΔR2 0.009-0.043).
4 | DISCUSSION
The high clinical variability in FSHD raises the question which factors
contribute to disease severity and penetrance. This study showed that
the D4Z4 repeat array size (mainly) in the range from 5 to 9 repeat
units accounted for only approximately 10% of the variance in disease
severity of FSHD, even though asymptomatic and non-penetrant gene
carriers showed significantly longer repeat array sizes than symptom-
atic individuals. All other familial factors, including shared genetic fac-
tors other than the FSHD1 mutation and shared environmental
factors within families, explained an additional 40% of the clinical vari-
ability in disease severity. Although unaffected gene carriers showed
higher Delta1 methylation levels, suggesting that chromatin modifiers
acting on the D4Z4 methylation level are probably involved, there
was no significant correlation between Delta1 methylation scores and
clinical severity. The identification of two outliers with a very severe
phenotype without an SMCHD1 pathogenic variant nor extremely low
Delta1 scores (−6 and −8), suggest that additional modifiers acting
through other pathways than the D4Z4 chromatin structure must be
involved.
Our results suggest that currently unknown disease modifying
factors acting on an individual level are involved. These factors proba-
bly include a combination of additional (epi)genetic factors as well as
organismal, environmental and lifestyle factors. Research on the latter
is limited. In the current study we found no influence of sex on dis-
ease severity. Possible protective effects of antioxidants and female
reproductive hormones are still under active investigation, but results
are contradictory.28–30 One study on aerobic exercise in FSHD
showed that it slows down disease progression in leg muscles.31
The characteristic pattern of muscle involvement in FSHD
prompted us to assess whether the influence of genetic and epige-
netic factors differs per body region or muscle group. Indeed, the
D4Z4 repeat array size had a stronger influence on the degree of
facial weakness than on the upper and lower extremity involvement.
This is in line with previous studies showing that patients with a
facial-sparing phenotype generally have repeat array sizes of >30 kb
(approximately 7 units).32–40 In contrast to the facial muscles, leg mus-
cle involvement was influenced by age, but hardly by D4Z4 repeat
array size. Remarkably, there was no difference in the influence of the
D4Z4 repeat array size and methylation between frequently involved
and frequently spared leg muscles.26,41
These findings raise the question whether the facial muscles, that
represent the most characteristic and often first symptom of FSHD,
are more sensitive to (differences in) DUX4 expression levels than
other muscles. There is no data on a histological or molecular level of
the facial muscles in FSHD because they cannot be biopsied, and also
on a clinical level knowledge is lacking. However, given the recent
studies suggesting a functional relationship between DUX4 and the
myogenic Pax3 and Pax7 homeodomain transcription factors, but not
with other related homeodomains such as Pitx2 and Tbx1, it is
TABLE 3 Results of nested linear regression analyses for disease severity and outcome measures per body region, showing the largest influence
of the D4Z4 repeat array size on the facial muscles
Model 1 (age, sex)
Model 2a (age, sex,
D4Z4 repeat array)
Model 2b (age, sex,
Delta1 score)
Model 3 (age, sex, D4Z4
repeat array, Delta1 score)
R2 ΔR2 from model 1 ΔR2 from model 1 ΔR2 from model 1
Overall disease severity
FSHD clinical score 0.128 0.118 0.013 0.131
Face
Facial score 0.025 0.313 0.043 0.356
Upper extremities
MFM upper extremity items 0.065 0.110 0.009 0.120
MRC-sum score upper extremity 0.047 0.183 0.014 0.197
Lower extremities
MFM lower extremity items 0.215 0.046 0.008 0.053
MRC-sum score lower extremity 0.151 0.066 0.009 0.074
Quantitative MRI fat fraction leg
muscles (n = 90)
0.303 0.006 0.009 0.015
Abbreviations: FSHD, facioscapulohumeral muscular dystrophy; MFM, motor function measure; MRC, Medical Research Council.
In each model independent factors were added to assess the additional explained variance from model 1 (ΔR2).
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tempting to speculate that facial muscles are more susceptible to
DUX4 damage during development.42,43
The small influence of the D4Z4 repeat array size on the degree
of leg muscle involvement suggests that these muscles are more sen-
sitive to modifying factors, or that compensation by other myogenic
homeobox proteins takes place. Because all patients with leg muscle
involvement also had some degree of facial and/or shoulder girdle
muscle involvement, DUX4 expression is likely to be required as a trig-
ger to induce disease activity in the leg muscles. This could indicate
that the involvement of leg muscles is results from a complex interplay
of downstream effects of DUX4 together with various modifying fac-
tors. Possibly, the influence of physical activity is larger for the lower
extremity muscles, as the level of activity is more variable for the leg
muscles than for the facial muscles. Additional research is required to
test this hypothesis.
A limitation of this study was the low proportion of individuals
with very short repeat array sizes (1-3 units). Generally, patients with
1 to 3 D4Z4 repeat units have a severe phenotype. The statistical
models used include the assumption that the relation between age
and disease severity is linear. Although on an individual level disease
progression is likely to be stepwise instead of gradually progressive,
this assumption probably is correct on a group level. Another limita-
tion was the presence of families with a limited number of participat-
ing family members. Although we included large families with up to
12 participating family members, there were also families with only
two included cases that were less suited to study the contribution of
familial factors. Finally, it is likely that some of the asymptomatic or
non-penetrant gene carriers were still pre-symptomatic and will
develop symptoms at a later age, even though their mean age was
high (49.8 years) and we excluded those aged under 25 years. A longi-
tudinal study would not only shed light on this question, but would
also provide information on the relation between (epi)genetic findings
and disease progression.
Although the D4Z4 repeat array sizes contribute to differences in
disease severity and penetrance, other unidentified factors must play
an important role. These modifying factors include chromatin modi-
fiers acting on D4Z4 methylation, but could include (epi)genetic as
well as organismal, environmental or lifestyle factors as well. Addition-
ally, there are probably differences in the sensitivity to the influence
of the D4Z4 locus itself and to various modifiers between different
muscle groups.
ACKNOWLEDGEMENTS
This study was supported by grants from the US National Institutes of
Health (NIH), National Institute of Neurological Disorders and Stroke
(NINDS) P01NS069539, the Prinses Beatrix Spierfonds (W.OR12-22
and W.OP14-01), and Stichting Spieren voor Spieren.
CONFLICTS OF INTEREST
S.M.M. is a consultant for Atyr-Pharma, receives grants from the NIH
National Institute of Neurological Disorders and Stroke
(P01NS069539), the Prinses Beatrix Spierfonds, the European Union
Framework Programme 7 (agreement 2012-305121, NEUROMICS),
the FSH Society, and Stichting Spieren voor Spieren.
B.G.M.E. receives grants from Prinses Beatrix Spierfonds, Associa-
tion Francaise contre les Myopathies, Stichting Spieren voor Spieren,
FSHD Stichting, NWO Dutch Organisation for scientific research.
The other authors have nothing to disclose.
ORCID
Karlien Mul http://orcid.org/0000-0001-8487-9478
REFERENCES
1. Deenen JC, Arnts H, van der Maarel SM, et al. Population-based inci-
dence and prevalence of facioscapulohumeral dystrophy. Neurology.
2014;83:1056-1059.
2. Mul K, Lassche S, Voermans NC, Padberg GW, Horlings CG, van
Engelen BG. What's in a name? The clinical features of facioscapulo-
humeral muscular dystrophy. Pract Neurol. 2016;16:201-207.
3. Tawil R, Forrester J, Griggs RC, et al. Evidence for anticipation and
association of deletion size with severity in facioscapulohumeral mus-
cular dystrophy. The FSH-DY Group. Ann Neurol. 1996;39:744-748.
4. Statland JM, Tawil R. Risk of functional impairment in facioscapulo-
humeral muscular dystrophy. Muscle Nerve. 2014;49:520-527.
5. Snider L, Geng LN, Lemmers RJ, et al. Facioscapulohumeral dystrophy:
incomplete suppression of a retrotransposed gene. PLoS Genet. 2010;
6:e1001181.
6. Dixit M, Ansseau E, Tassin A, et al. DUX4, a candidate gene of facios-
capulohumeral muscular dystrophy, encodes a transcriptional activator
of PITX1. Proc Natl Acad Sci U S A. 2007;104:18157-18162.
7. Lemmers RJ, van der Vliet PJ, Klooster R, et al. A unifying genetic
model for facioscapulohumeral muscular dystrophy. Science. 2010;
329:1650-1653.
8. Wijmenga C, Hewitt JE, Sandkuijl LA, et al. Chromosome 4q DNA
rearrangements associated with facioscapulohumeral muscular dystro-
phy. Nat Genet. 1992;2:26-30.
9. Lemmers RJ, Tawil R, Petek LM, et al. Digenic inheritance of an
SMCHD1 mutation and an FSHD-permissive D4Z4 allele causes
facioscapulohumeral muscular dystrophy type 2. Nat Genet. 2012;44:
1370-1374.
10. van den Boogaard ML, Lemmers RJ, Balog J, et al. Mutations in
DNMT3B modify epigenetic repression of the D4Z4 repeat and the
penetrance of facioscapulohumeral dystrophy. Am J Hum Genet. 2016;
98:1020-1029.
11. Lemmers RJ, van der Vliet PJ, van der Gaag KJ, et al. Worldwide popu-
lation analysis of the 4q and 10q subtelomeres identifies only four dis-
crete interchromosomal sequence transfers in human evolution.
Am J Hum Genet. 2010;86:364-377.
12. Lunt PW, Jardine PE, Koch MC, et al. Correlation between fragment
size at D4F104S1 and age at onset or at wheelchair use, with a possi-
ble generational effect, accounts for much phenotypic variation in
4q35-facioscapulohumeral muscular dystrophy (FSHD). Hum Mol
Genet. 1995;4:951-958.
13. Goto K, Nishino I, Hayashi YK. Very low penetrance in 85 Japanese
families with facioscapulohumeral muscular dystrophy 1A. J Med
Genet. 2004;41:e12.
14. Ricci E, Galluzzi G, Deidda G, et al. Progress in the molecular diagnosis
of facioscapulohumeral muscular dystrophy and correlation between
the number of KpnI repeats at the 4q35 locus and clinical phenotype.
Ann Neurol. 1999;45:751-757.
15. Tonini MM, Passos-Bueno MR, Cerqueira A, Matioli SR, Pavanello R,
Zatz M. Asymptomatic carriers and gender differences in facioscapulo-
humeral muscular dystrophy (FSHD). Neuromuscul Disord. 2004;14:
33-38.
16. Nikolic A, Ricci G, Sera F, et al. Clinical expression of facioscapulohum-
eral muscular dystrophy in carriers of 1-3 D4Z4 reduced alleles: expe-
rience of the FSHD Italian National Registry. BMJ Open. 2016;6:
e007798.
526 MUL ET AL.
17. Statland JM, Donlin-Smith CM, Tapscott SJ, Lemmers RJ, van der
Maarel SM, Tawil R. Milder phenotype in facioscapulohumeral dystro-
phy with 7-10 residual D4Z4 repeats. Neurology. 2015;85:2147-2150.
18. Zatz M, Marie SK, Cerqueira A, Vainzof M, Pavanello RC,
Passos-Bueno MR. The facioscapulohumeral muscular dystrophy
(FSHD1) gene affects males more severely and more frequently than
females. Am J Med Genet. 1998;77:155-161.
19. Lemmers RJ, Wohlgemuth M, van der Gaag KJ, et al. Specific
sequence variations within the 4q35 region are associated with facios-
capulohumeral muscular dystrophy. Am J Hum Genet. 2007;81:
884-894.
20. Scionti I, Fabbri G, Fiorillo C, et al. Facioscapulohumeral muscular dys-
trophy: new insights from compound heterozygotes and implication
for prenatal genetic counselling. J Med Genet. 2012;49:171-178.
21. Sacconi S, Lemmers RJ, Balog J, et al. The FSHD2 gene SMCHD1 is a
modifier of disease severity in families affected by FSHD1. Am J Hum
Genet. 2013;93:744-751.
22. Lemmers RJ, Goeman JJ, van der Vliet PJ, et al. Inter-individual differ-
ences in CpG methylation at D4Z4 correlate with clinical variability in
FSHD1 and FSHD2. Hum Mol Genet. 2015;24:659-669.
23. Lamperti C, Fabbri G, Vercelli L, et al. A standardized clinical evalua-
tion of patients affected by facioscapulohumeral muscular dystrophy:
the FSHD clinical score. Muscle Nerve. 2010;42:213-217.
24. Berard C, Payan C, Hodgkinson I, Fermanian J, MFM Collabrative
Study Group. A motor function measure for neuromuscular diseases.
Construction and validation study. Neuromuscul Disord. 2005;15:
463-470.
25. Council MR. Aids to the Investigation of Peripheral Nerve Injuries.
London, England: Her Majesty's Stationary Office; 1976.
26. Mul K, Vincenten SCC, Voermans NC, et al. Adding quantitative mus-
cle MRI to the FSHD clinical trial toolbox. Neurology. 2017;89:
2057-2065.
27. Kuk JL, Saunders TJ, Davidson LE, Ross R. Age-related changes in total
and regional fat distribution. Ageing Res Rev. 2009;8:339-348.
28. Passerieux E, Hayot M, Jaussent A, et al. Effects of vitamin C,
vitamin E, zinc gluconate, and selenomethionine supplementation on
muscle function and oxidative stress biomarkers in patients with
facioscapulohumeral dystrophy: a double-blind randomized controlled
clinical trial. Free Radic Biol Med. 2015;81:158-169.
29. Teveroni E, Pellegrino M, Sacconi S, et al. Estrogens enhance myoblast
differentiation in facioscapulohumeral muscular dystrophy by antago-
nizing DUX4 activity. J Clin Invest. 2017;127:1531-1545.
30. Mul K, Horlings CGC, Voermans NC, Schreuder THA, van
Engelen BGM. Lifetime endogenous estrogen exposure and disease
severity in female patients with facioscapulohumeral muscular dystro-
phy. Neuromuscul Disord. 2018;28:508-511.
31. Janssen B, Voet N, Geurts A, van Engelen B, Heerschap A. Quantita-
tive MRI reveals decelerated fatty infiltration in muscles of active
FSHD patients. Neurology. 2016;86:1700-1707.
32. Butz M, Koch MC, Muller-Felber W, Lemmers RJ, van der Maarel SM,
Schreiber H. Facioscapulohumeral muscular dystrophy. Phenotype-
genotype correlation in patients with borderline D4Z4 repeat num-
bers. J Neurol. 2003;250:932-937.
33. Mostacciuolo ML, Pastorello E, Vazza G, et al. Facioscapulohumeral
muscular dystrophy: epidemiological and molecular study in a
north-east Italian population sample. Clin Genet. 2009;75:550-555.
34. Felice KJ, North WA, Moore SA, Mathews KD. FSH dystrophy 4q35
deletion in patients presenting with facial-sparing scapular myopathy.
Neurology. 2000;54:1927-1931.
35. Hassan A, Jones LK Jr, Milone M, Kumar N. Focal and other unusual
presentations of facioscapulohumeral muscular dystrophy. Muscle
Nerve. 2012;46:421-425.
36. Pastorello E, Cao M, Trevisan CP. Atypical onset in a series of
122 cases with FacioScapuloHumeral Muscular Dystrophy. Clin Neurol
Neurosurg. 2012;114:230-234.
37. Jordan B, Eger K, Koesling S, Zierz S. Camptocormia phenotype of
FSHD: a clinical and MRI study on six patients. J Neurol. 2011;258:
866-873.
38. Felice KJ, Whitaker CH. The clinical features of facioscapulohumeral
muscular dystrophy associated with borderline (>/=35 kb) 4q35 EcoRI
fragments. J Clin Neuromuscul Dis. 2005;6:119-126.
39. van der Kooi AJ, Visser MC, Rosenberg N, et al. Extension of the clini-
cal range of facioscapulohumeral dystrophy: report of six cases. J Neu-
rol Neurosurg Psychiatry. 2000;69:114-116.
40. Krasnianski M, Neudecker S, Eger K, Schulte-Mattler W, Zierz S.
Facioscapulohumeral muscular dystrophy. The spectrum of clinical
manifestations and molecular genetic changes. Nervenarzt. 2003;74:
151-158.
41. Tasca G, Monforte M, Ottaviani P, et al. Magnetic resonance imaging
in a large cohort of facioscapulohumeral muscular dystrophy patients:
pattern refinement and implications for clinical trials. Ann Neurol.
2016;79:854-864.
42. Bosnakovski D, Toso EA, Hartweck LM, et al. The DUX4 homeodo-
mains mediate inhibition of myogenesis and are functionally
exchangeable with the Pax7 homeodomain. J Cell Sci. 2017;130:
3685-3697.
43. Banerji CRS, Panamarova M, Hebaishi H, et al. PAX7 target genes are
globally repressed in facioscapulohumeral muscular dystrophy skeletal
muscle. Nat Commun. 2017;8:2152.
How to cite this article: Mul K, Voermans NC, Lemmers RJ,
et al. Phenotype-genotype relations in facioscapulohumeral
muscular dystrophy type 1. Clin Genet. 2018;94:521–527.
https://doi.org/10.1111/cge.13446
MUL ET AL. 527
